Histone deacetylase inhibitor restores surfactant protein-C expression in alveolar-epithelial type II cells and attenuates bleomycin-induced pulmonary fibrosisin vivo-Reference-Cited by-同舟云学术

Histone deacetylase inhibitor restores surfactant protein-C expression in alveolar-epithelial type II cells and attenuates bleomycin-induced pulmonary fibrosisin vivo

Published:2015-07-07 Issue:8 Volume:41 Page:422-434
ISSN:0190-2148
Container-title:Experimental Lung Research
language:en
Short-container-title:Experimental Lung Research

Author:

Ota Chiharu,Yamada Mitsuhiro,Fujino Naoya,Motohashi Hozumi,Tando Yukiko,Takei Yusuke,Suzuki Takaya,Takahashi Toru,Kamata Satoshi,Makiguchi Tomonori,Yamaya Mutsuo,Kubo Hiroshi

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Pulmonary and Respiratory Medicine,Molecular Biology

Link

http://www.tandfonline.com/doi/pdf/10.3109/01902148.2015.1060275

Reference44 articles.

1. Targeted Injury of Type II Alveolar Epithelial Cells Induces Pulmonary Fibrosis

2. The increase of microRNA-21 during lung fibrosis and its contribution to epithelial-mesenchymal transition in pulmonary epithelial cells

3. Foxm1 transcription factor is required for lung fibrosis and epithelial-to-mesenchymal transition

4. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Histone deacetylases: potential therapeutic targets for idiopathic pulmonary fibrosis;Frontiers in Cell and Developmental Biology;2024-08-13

2. Mechanisms of Bleomycin-induced Lung Fibrosis: A Review of Therapeutic Targets and Approaches;Cell Biochemistry and Biophysics;2024-07-02

3. Synergistic Power of Piceatannol and/or Vitamin D in Bleomycin-Induced Pulmonary Fibrosis In Vivo: A Preliminary Study;Biomedicines;2023-09-27

4. Potential Therapeutic Targets of Resveratrol in the Prevention and Treatment of Pulmonary Fibrosis;Frontiers in Bioscience-Landmark;2023-09-14

5. Recombinant CXCL17 Treatment Alleviates Hyperoxia-Induced Lung Apoptosis and Inflammation In Vivo and Vitro by Activating the AKT Pathway: A Possible Therapeutic Approach for Bronchopulmonary Dysplasia;Molecular Biotechnology;2023-09-14